Pay in 4 interest-free payments of $5.34 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Baseline albuminuria levels, their trajectory over time, and the degree of response to interventions provide actionable data for optimizing therapy
AA received research grants and lecture or advisory board fees from MSD, AstraZeneca, Novartis, Boehringer Ingelheim, Sanofi, Mediolanum, Janssen, Novo Nordisk, Lilly, Servier and Takeda
What you need to know As more people turn to GLP-1 medications to help them achieve their weight loss goals, more people are coming to realize the significant side effects of rapid weight loss, which can affect nearly every part of their bodies
There has also been impact on decreasing the chance of developing or recurrent cardiovascular disease such as heart attacks or stroke.
10.1001/jamainternmed.2024.4369 Summary Keywords cardiovascular disease, cardiovascular outcome, glucagon-like peptide-1 receptor agonists, heart failure, obesity Citation Turkistani Y (2025) Glucagon-like peptide-1 receptor agonists: a review from a cardiovascular perspective
US$ 21.53
US$ 23.68
US$ 26.58
US$ 22.07
US$ 20.91
US$ 23.92
US$ 24.52
